Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of ...

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improv ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today ...

For inspiration on how to make the most of your second reset of the school year, we checked in with contributors to The ...

MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Repurposing traditional professional learning communities as teacher-led teams builds trust and strengthens instructional alignment.

Akari Therapeutics, Plc, an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...

Investing.com -- East Star Resources Plc (LSE:EST) has reported positive drilling results from its Verkhuba Copper Deposit in Kazakhstan, confirming deep mineralisation and shallow extensions to the ...

LUMRYZ is only currently approved for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and Avadel does not market, promote or offer patient support services ...

Antipa has lifted gold equivalent resources at the Minyari project in WA's Paterson Province to 3.3Moz in an updated MRE.